tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2020 Nov 2;8(4):E640.
doi: 10.3390/vaccines8040640.
Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
Mikhail P Kostinov[SUP] 1 2 [/SUP], Elena A Latysheva[SUP] 3 [/SUP], Aristitsa M Kostinova[SUP] 3 [/SUP], Nelly K Akhmatova[SUP] 1 [/SUP], Tatyana V Latysheva[SUP] 3 [/SUP], Anna E Vlasenko[SUP] 4 [/SUP], Yulia A Dagil[SUP] 3 [/SUP], Ekaterina A Khromova[SUP] 1 [/SUP], Valentina B Polichshuk[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice.
Methods: In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018-2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used.
Results: All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels.
Conclusion: Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies' presence or absence before. In CVID patients search of new regimens should be continued.
Keywords: CVID; adjuvanted QIV; azoximer bromide; immunogenicity; influenza; seropositive/seronegative.
. 2020 Nov 2;8(4):E640.
doi: 10.3390/vaccines8040640.
Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
Mikhail P Kostinov[SUP] 1 2 [/SUP], Elena A Latysheva[SUP] 3 [/SUP], Aristitsa M Kostinova[SUP] 3 [/SUP], Nelly K Akhmatova[SUP] 1 [/SUP], Tatyana V Latysheva[SUP] 3 [/SUP], Anna E Vlasenko[SUP] 4 [/SUP], Yulia A Dagil[SUP] 3 [/SUP], Ekaterina A Khromova[SUP] 1 [/SUP], Valentina B Polichshuk[SUP] 1 [/SUP]
Affiliations
- PMID: 33147763
- DOI: 10.3390/vaccines8040640
Abstract
Background: Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice.
Methods: In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018-2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used.
Results: All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels.
Conclusion: Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies' presence or absence before. In CVID patients search of new regimens should be continued.
Keywords: CVID; adjuvanted QIV; azoximer bromide; immunogenicity; influenza; seropositive/seronegative.